一年两针的降脂药京沪开打，一针价格近万元仍供不该求？
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2023.10.</span><strong style="color: blue;">17</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_jpg/75aM8OyvVZWrCKbykaXltqAFcF9wfviaEMrmMf2pfiaRhDyvxZt00P10fB3PGhibicaMDMclCdHcoXeXocD3GaERNQ/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">本文字数：872，阅读时<span style="color: black;">成长</span>约1分钟</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">导读</span></strong><span style="color: black;">：本周北京大学<span style="color: black;">第1</span>医院心血管内科首席专家霍勇教授和复旦大学<span style="color: black;">附庸</span>中山医院心内科副<span style="color: black;">专家</span>钱菊英教授分别为<span style="color: black;">病人</span>开出北京和上海的首张英克司兰处方单，<span style="color: black;">日前</span>长三角的首针注射<span style="color: black;">已然</span>完成。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">作者 | </span></strong><span style="color: black;"><span style="color: black;">第1</span>财经 钱童心</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">诺华<span style="color: black;">机构</span>靶向PCSK9的长效降脂小干扰核酸（siRNA）<span style="color: black;">药品</span>英克司兰（inclisiran）自今年8月在华<span style="color: black;">获准</span>后，日前正式在国内开打。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">第1</span>财经记者<span style="color: black;">认识</span>到，本周北京大学<span style="color: black;">第1</span>医院心血管内科首席专家霍勇教授和复旦大学<span style="color: black;">附庸</span>中山医院心内科副<span style="color: black;">专家</span>钱菊英教授分别为<span style="color: black;">病人</span>开出北京和上海的首张英克司兰处方单，<span style="color: black;">日前</span>长三角的首针注射<span style="color: black;">已然</span>完成。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">这标志着我国心血管<span style="color: black;">疾患</span>治疗已加速进入小核酸<span style="color: black;">药品</span>时代，开启了血脂管理的新篇章。英克司兰给药间隔长达半年，<span style="color: black;">能够</span>为<span style="color: black;">病人</span>省去<span style="color: black;">更加多</span>麻烦，节约<span style="color: black;">更加多</span>时间。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">英克司兰的定价问题<span style="color: black;">始终</span>备受关注。<span style="color: black;">根据</span>美国对该<span style="color: black;">药品</span>超过3000美元一针的定价，半年的治疗<span style="color: black;">花费</span>就超过2万元人民币，一年的花费要超过4万元人民币，<span style="color: black;">做为</span>慢性病用药可及性仍然较低。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">第1</span>财经记者从多方<span style="color: black;">认识</span>到，英克司兰在国内的最新定价为一针9988元人民币，这较美国的治疗<span style="color: black;">花费</span>减半。英克司兰首针注射后第3个月需注射第2针，随后每半年一针。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/75aM8OyvVZWrCKbykaXltqAFcF9wfviaEMrmMf2pfiaRhDyvxZt00P10fB3PGhibicaMDMclCdHcoXeXocD3GaERNQ/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">尽管一针近万元的价格<span style="color: black;">针对</span><span style="color: black;">病人</span>自费而言并<span style="color: black;">不方便</span>宜，但<span style="color: black;">因为</span>该<span style="color: black;">药品</span>与<span style="color: black;">此刻</span>市场上<span style="color: black;">已然</span>存在的PCSK9治疗<span style="color: black;">药品</span>相比，能够更加长效地降低LDL-C（低密度脂蛋白胆固醇），为他汀类<span style="color: black;">药品</span>不耐受、血脂<span style="color: black;">掌控</span>不达标的<span style="color: black;">病人</span><span style="color: black;">供给</span><span style="color: black;">更加多</span><span style="color: black;">选取</span><span style="color: black;">方法</span>。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">英克司兰尚未开打前就受到<span style="color: black;">极重</span>关注。<span style="color: black;">按照</span>已<span style="color: black;">发布</span>的<span style="color: black;">全世界</span><span style="color: black;">重要</span>性Ⅲ期临床<span style="color: black;">实验</span>结果，英克司兰每年仅需皮下注射两针，<span style="color: black;">就可</span><span style="color: black;">很久</span><span style="color: black;">安稳</span>地降低LDL-C水平，降幅<span style="color: black;">达到</span>50%以上。<span style="color: black;">关联</span>专家介绍<span style="color: black;">叫作</span>，血脂<span style="color: black;">掌控</span><span style="color: black;">欠好</span>、依从性较差的<span style="color: black;">病人</span>有望最先从该<span style="color: black;">药品</span>中受益。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">第1</span>财经记者向医院方面<span style="color: black;">认识</span>英克司兰的供应<span style="color: black;">状况</span>，一位心内科专家<span style="color: black;">暗示</span>：“<span style="color: black;">日前</span>这款<span style="color: black;">药品</span><span style="color: black;">能够</span>说是供<span style="color: black;">不该</span>求。”但<span style="color: black;">无</span>透露<span style="color: black;">详细</span>的等待时间。针对英克司兰的供应<span style="color: black;">状况</span>，诺华中国方面<span style="color: black;">无</span>向<span style="color: black;">第1</span>财经记者<span style="color: black;">回复</span><span style="color: black;">更加多</span>细节。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">诺华方面此前介绍，英克司兰在递交新药申请9个月后就在中国<span style="color: black;">获准</span>，快速的审批流程使得<span style="color: black;">更加多</span><span style="color: black;">病人</span>能够受益于创新疗法。</span></p><strong style="color: blue;"><span style="color: black;"><span style="color: black;">微X</span>编辑</span></strong><span style="color: black;"> | 立早</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">举荐</span>阅读</strong></span>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><a style="color: black;"><span style="color: black;"><strong style="color: blue;">突发！美国3号<span style="color: black;">名人</span>被罢免</strong></span></a></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/75aM8OyvVZUibENODMTEF8HEMSJ0Yb9U8bGE9SobIKUiaXQok16XnDksQlr2nNdHAXBgLJicoJCx5lJLmoj5riauHA/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/75aM8OyvVZWo7u29SFKLeRudIyT20DgymC3EMcj91GD2rv6eaqcfsKopPzfGST1fXy9ssnicBuKY7xYCOicoRRBQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><img src="https://mmbiz.qpic.cn/mmbiz_jpg/75aM8OyvVZVkH4Yaic3iaKat4A4NBlmcHFpMvUnCWdQ61fCSicCmUMPogwdc1f7yA563Jibicu0k1vNnv5kVWNVMXzg/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
页:
[1]